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1Chapter
Advances in Minimally Invasive 
Surgery for Lung Cancer
Rachit Shah and Nils-Tomas Delagar McBride
Abstract
Over the last 25 years, improvement in instrumentation and surgical techniques 
has led to widespread adaptation of thoracoscopic (VATS) surgery in the field of 
thoracic oncology. What once was a niche operation like VATS wedge resection 
to now hybrid VATS chest wall resections, and advanced surgeries like broncho-
plasty and sleeve resections are done with VATS. This has led to improved surgical 
outcomes for our patients and increased use of surgery in the treatment of chest 
disease. We review the history of VATS and its current state with most recent 
changes and upgrades in the technique in this chapter. We review the advancement 
in uniportal VATS, robotic assisted resection, complex VATS resection, and awake 
lung surgery with VATS.
Keywords: VATS, uniportal, robotics, awake VATS, hybrid resections
1. History of thoracoscopy
While the modern era of thoracoscopy begins in the early 1990s and includes 
Giancarlo Roviaro’s report of the first thoracoscopic lobectomy as a major milestone 
[1], the term thoracoscopy dates back to a procedure performed by Francis Richard 
Cruise and Samuel Gordon in 1865 [2]. Using a device similar to the “Leichtleiter” 
used by Bozzini with a light source improved by Antonin Jean Desormeaux, Cruise 
examined the pleural space of an 11 years old suffering from an empyema and a 
pleurocutaneous fistula. Several years later, in 1882, coincidentally the year Robert 
Koch discovered Mycobacterium tuberculosis [3], Carlo Forlanini observed that spon-
taneous pneumothorax could collapse cavitary lesions and lead to their resolution 
[4]. From this observation, he introduced a procedure of inducing artificial closed 
pneumothoraces by inserting a needle in the anterior axillary line and forcing air 
into the pleural space, the first minimally invasive thoracic procedure.
Though he is considered by many to be the father of thoracoscopy, Hans 
Christian Jacobeus published his eponymous Jacobeus Operation in 1910; this 
operation involved inducing pneumothorax, inserting a thoracoscope through 
one incision, and introducing an galvanocautery instrument in through a separate 
incision for the purpose of releasing adhesions to allow the lung collapse to treat 
pulmonary tuberculosis [5]. Subsequently, antibiotics, improved anesthetics, and 
intraoperative oxygen delivery, thoracoscopy was neglected as a therapeutic option 
for most of the twentieth century until the modern era.
Attributed in large part to fiber optics for light transmission, enhanced image 
processing and rendering, and the advent of the surgical staplers, interest in VATS 
was piqued. The classic three-port technique focused the camera from hip-to-head 
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while increased experience determined that a modified approach should focus 
from umbilicus-to-shoulder. Aside from traditional three-port VATS technique, 
some procedures, including thoracic sympathectomy, have been performed via 
needlescopic VATS as well as two-port and uniportal VATS. Additionally, robotic 
assisted thoracic surgery (RATS) can serve a role in thoracic surgery, particularly 
for mediastinal procedures. Each of these different techniques has the potential to 
serve an important role as part of the thoracic surgeon’s armamentarium [6].
2. VATS lobectomy
As mentioned in the previous section, Roviaro reported the first VATS lobec-
tomy in 1991. However, in 1993, only 2% of the cases reported by the Video 
Assisted Study Group were VATS lobectomies while 49% were wedge resections. 
As reports continued to show the feasibility of VATS lobectomies as well as possible 
advantages, familiarity with the procedure improved technique. Even so, skepti-
cism remained for the use of VATS for the treatment of non-small cell lung cancer 
(NSCLC). The results of a randomized control trial by Kirby et al. [7] failed to 
demonstrate the superiority of VATS though it also failed to demonstrate inferiority. 
In this study, 30 patients were randomized to the traditional muscle-sparing thora-
cotomy while 24 were put into the VATS group. No difference was found between 
the duration of chest tube drainage, hospital length of stay, pain score, or time prior 
to returning to work. The study specifically expressed concerns about the adequacy 
of lymph node dissection for an operation intended for malignancy.
McKenna et al. reviewed 298 cases of patients that underwent VATS lobectomy 
and lymph node dissection for NSCLC with the intent of determining adequacy of 
resection [8]. Their multi-institutional review included patients with stage I to IIIA 
and featured a 6% conversion rate with a single report of an incisional recurrence. 
In this study, the survival rate at 4 years for patients with stage I disease was 70%. 
Comparatively, Li and Wang [9] retrospectively evaluated outcomes for 76 patients 
that underwent lobectomies with lymph node dissection via VATS or thoracotomy 
for clinical N0 disease that was discovered to be pathologic N2 NSCLC. In their 
study, the number of lymph nodes recovered and the number of stations sampled 
were similar. The survival and disease-free survival rates are presented in Table 1. 
In addition to these reported survival and disease-free survival rates, VATS patients 
had shorter operative times and less blood loss.
A subsequent larger study was performed by Onaitis et al. [10] on VATS lobec-
tomies for benign and malignant disease including 500 patients. Of these lobec-
tomies, 83.2% were performed for NSCLC with an overall conversion rate of 1.6% 
(8 of 500). The pathologic stage of the patients included in this study were stage I 
(55.3%), stage II (9.6%) and stage III or greater (10.6%). The overall 2-year survival 
rate in the patients with stage I NSCLC and stage II was comparable to those under-
going thoracotomy (85% vs. 77%). Additionally, perioperative mortality for benign 
pathologies was 0% while it was 1% for malignant pathologies.
1-year disease-free 
survival
3-year disease-free 
survival
1-year 
survival
3-year 
survival
VATS 82.6% 49.3% 84.9% 64.0%
Thoracotomy 72.0% 51.3% 71.2% 42.7%
Table 1. 
Comparative survival rates.
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Whitson et al. [11] analyzed 147 patients who underwent lobectomies for stage I 
NSCLC (59 by VATS and 88 by thoracotomy). In this particular study, patients who 
underwent thoracotomy had a larger yield of nodes and shorter time in the ICU, 
potentially because of the additional comorbidities reported in the VATS patients. 
However, no significant differences were found in operative times, length of hospi-
tal stay, or median survival.
3. Long-term outcomes of VATS lobectomy for NSCLC
To justify the continued use of VATS for lobectomies as treatment for NSCLC, 
data continues to be collected and reported by many groups. Multi-institutional 
experience of 145 patients with clinical stage IA NSCLC less than or equal to 2 
cm was reported by Shigemura et al. [12]. For this study, three approaches were 
utilized: complete thoracoscopic technique without any rib spreading, assisted 
VATS, which included VATS with a mini-thoracotomy and open thoractomy. 
The overall 5-year survival rates did not differ significantly between techniques 
(VATS—96.7%, assisted VATS—95.2%, and open—97.2%). Higuchi et al. [13] 
also reported their experience of 160 patients with stage IA NSCLC with patients 
who underwent VATS lobectomy and open thoracotomy. The reported 5-year 
disease-free survival was equivalent with 88% in the VATS group and 77.1% in the 
thoracotomy group. The 5-year overall survival for pathologic stage IA NSCLC 
was 94.8% in the VATS group and 96.2% in the thoracotomy group, showing no 
statistical difference in survival. Lee et al. [14] performed a retrospective review 
of patients who underwent lobectomy for NSCLC, from their institution using 
propensity-matched scores in 416 patients. The review included clinical stage I 
to III with the majority being stage IA. The 3- and 5-year overall survival for 
the patients with clinical stage IA who underwent VATS lobectomy were 87.4 
and 76.5%, respectively, and 81.6 and 77.5% for thoracotomy. Their analysis also 
showed no inferiority of VATS lobectomy for early stage NSCLC. Murakawa et al. 
[15] also evaluated survival outcomes in patients with early stage NSCLC and 
found VATS and open thoracotomy to be equivalent. Yang et al. [16] queried the 
national cancer database to evaluate the national survival outcomes following 
VATS versus open lobectomy for stage I NSCLC. After propensity score matching 
2928 patients were included in the final analysis. In the matched patients there was 
no difference in 5-year survival between VATS and open thoracotomy, 66.3 and 
65.8%, respectively. Data published by Flores et al. [17], which included intent to 
treat analysis in 741 patients (398 VATS and 343 open thoracotomy) demonstrating 
similar 5 year survival. The majority of their patients treated with lobectomy were 
clinical stage IA and demonstrated 79% 5-year survival in the VATS group and 75% 
in the open thoracotomy group (Table 2).
Reference Year # of patients VATS Open
Shigemura et al. [12] 2006 145 96.7% 97.2%
Flores et al. [17] 2009 741 79% 75%
Higuchi et al. [13] 2014 160 94.8% 96.2%
Lee et al. [14] 2013 416 76.5% 77.5%
Yang et al. [18] 2017 2928 66.3% 65.8%
Table 2. 
Five-year overall survival.
Update in Respiratory Diseases
4
4. Mediastinal lymph node dissection (MLND) via VATS
An essential component of each complete pulmonary resection for NSCLC is 
an adequate mediastinal lymph node dissection (MLND). With the advent of VATS 
lobectomy particularly for NSCLC, the efficacy of a VATS MLND has been evalu-
ated in comparison to MLND via thoracotomy. The National Comprehensive Cancer 
Network’s (NCCN) NSCLC Database was evaluated by D’Amico et al. [19] to com-
pare VATS MLND to MLND via thoracotomy. The number of lymph node stations 
evaluated by both techniques was at least 3 and the number of N2 nodes evaluated 
by both techniques was not significantly different. A single institution randomized 
control trial reported by Palade et al. [20] included 66 patients with stage 1 NSCLC. 
In this study, there was no statistically significant difference in the overall number 
of lymph nodes sampled or the number of lymph nodes in each station. Because 
VATS MLND has comparable efficacy to open dissection, adequate lymph node 
dissection can be performed thoracoscopically.
5. Clinical advantages of VATS lobectomy vs. thoracotomy
Multiple studies have documented several advantages of VATS lobectomies 
including improved quality of life, decreased postoperative pain, and shorter hos-
pital stays. A retrospective study by Villazmizar et al. [21] evaluated 1097 patients 
that underwent lobectomies with 697 lobectomies via VATS and 382 lobectomies 
via thoracotomy. In reviewing these cases, the incidence of postoperative compli-
cations, including atrial fibrillation, atelectasis, prolonged air leak, transfusion 
requirements, pneumonia, renal failure death, and shorter hospital stay, were 
all found to be less common in the VATS lobectomy group. Paul et al. [22] found 
similar results in evaluating the STS database and reviewing 6323 lobectomies, 
5024 via thoracotomy and 1281 via VATS. Propensity matched analysis of these 
cases found that 73% of VATS patients experienced no complications while 65.3% 
of thoracotomy patients had no complications. Furthermore, patients undergoing 
VATS lobectomy in this review had a lower incidence of arrhythmias, reintubations, 
and blood transfusion as well as shorter duration of chest tube drainage and length 
of stay.
Predictably, patients requiring pulmonary resections for management of NSCLC 
often suffer from decreased pulmonary function, which makes them high risk. 
Because VATS has reduced the risks associated with lobectomy, patients previ-
ously considered prohibitive risks are potentially resectable. Donahoe et al. [23] 
evaluated a cohort of 608 patients (including 72 high risk and 536 standard risk) 
that underwent lobectomy for NSCLC. For those patients who underwent a VATS 
lobectomy, there was no difference in complication rate or overall survival between 
high risk and standard risk patients. Another study by Bertani et al. [24] found that 
VATS lobectomy patients with reduced preoperative FEV1 had similar outcomes as 
those with normal preoperative FEV1, despite a longer hospital stay. Patient with a 
predicted postoperative FEV1% of less than 60% had an average length of stay of 
8.7 days while those with a predicted postoperative FEV1% of greater than 60% was 
6.8 days (8.7 vs. 6.8 days, p = 0.05) (Table 3).
In light of these advantages, it is important to establish not only efficacy but 
cost effectiveness as a measure of quality. Swanson et al. [25] evaluated the costs of 
open versus VATS lobectomy for 3961. In this study, patients who underwent a VATS 
lobectomy had a shorter length of stay, less adverse events, and cost the hospital less 
than an open lobectomy.
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6. Clinical advantages of VATS lobectomy vs. thoracotomy
As a direct result of the advantages and similar survival rates for patients after 
VATS lobectomy for NSCLC, many institutions have adopted this surgical approach. 
In addition to VATS lobectomies, other anatomic resections have been performed 
via VATS.
Recent data have indicated that an anatomic segmentectomy can be considered 
an acceptable operation to obtain an R0 resection for small stage I NSCLC lesions. 
In a study reviewing 225 anatomic segmentectomies by Schuchert et al. [26], VATS 
segmentectomies were compared to those performed via thoracotomy demonstrating 
similar overall mortality, complications, recurrence rates, and overall survival.
Liu et al. [27] difference was seen in transfusion rates, number of lymph nodes 
dissected, estimated blood loss, duration of chest tube drainage, overall complica-
tion rates, or length of hospital stay. Operative time was longer in the VATS group 
while postoperative mean pain scores were higher in the higher in the thoracotomy 
group. From their data, they conclude that VATS pneumonectomy is a safe tech-
nique for either benign or malignant disease.
7. Development of single port VATS
The first description of single port VATS by Rocco et al. [28] was published in 2004. 
Initially used for diagnosis or treatment of primary spontaneous pneumothorax, 
the uses of single port VATS expanded to include management of pleural effusions, 
nonanatomic wedge resections, and diagnostic thoracoscopy for lung cancer during 
this study’s 10 year experience. The conversion rate to a 2 or 3 port VATS or mini thora-
cotomy was 3.7%. Xie et al. [29] reported their single-institution experience of single 
port VATS in 1063 cases with a conversion rate of 4.6%. Institutional data reported by 
Shih et al. [30] comparing single port VATS to multiport VATS for anatomic segmen-
tectomies in treating primary lung cancer indicated similar operative outcomes in the 
two propensity matched groups.
Single port VATS has been evaluated for safety and efficacy in the treatment of 
NSCLC. Comparing VATS and single port VATS lobectomy patients, Dai et al. [31] 
reported that single port VATS patients reported a higher satisfaction score, less 
Ppo 
FEV1%
n Grade I Grade II Grade 
IIIa
Grade 
IIIb
p-value† LOS, Mean 
(±SD)
p-value‡
<40% 2 0 (—) 1 (100.00) 0 (—) 0 (—) n.s 5.90 (±2.23) n.s
≥40% 98 22 (45.83) 24 (50.00) 1 (2.08) 1 (2.08) 7.18 (±3.83)
<50% 4 1 (50.00) 1 (50.00) 0 (—) 0 (—) n.s 9.18 (±6.31) n.s
≥50% 96 21 (44.68) 24 (51.06) 1 (2.13) 1 (2.13) 7.10 (±3.72)
<60% 18 4 (40.00) 4 (40.00) 1 (10.00) 1 (10.00) 0.067 8.74 (±4.79) 0.05
≥60% 82 18 (46.15) 21 (53.85) 0 (—) 0 (—) 6.80 (±3.52)
LOS, overall hospital length of stay; n.s., not significant; ppo-FEV1, predicted postoperative forced expiratory 
volume in 1 s; SD, standard deviation.
†Fisher’s exact test.
‡t-test with equal or unequal variance.
Table 3. 
Complications of patients undergoing video-assisted thoracic surgery lobectomy based on different ppo-FEV1 
cut-offs [24].
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postoperative pain, and less blood loss. Fan et al. [32] reported a similar operative 
time and number of lymph nodes dissected in both single port VATS and open 
lobectomies for locally advanced NSCLC. In this study, single port patients had a 
shorter period of chest tube drainage and length of hospital stay but a higher com-
plication rate than thoracotomy. The complications studied included prolonged air 
leak, atrial fibrillation, bleeding, pneumonia, bronchopleural fistula, chylothorax, 
death, and 30-day mortality. However, neither study reported data on recurrence 
rates of overall survival.
8. Development of robotic-assisted VATS
With data indicating that VATS is safe and efficacious for the resection of 
NSCLC as well as having a variety of advantages over open surgery, it has been 
established as the preferred technique. However, with the availability of the robotic 
assistance, techniques for robotic procedures have been developed and examined. 
Utilizing three robotic ports as well as an assistance port, Melfi et al. [33] reported 
their early experience using the Da Vinci platform, describing lobectomies, enucle-
ations, excisions, and bulla stitching. Single institution experiences have reported 
safety and shown similar outcomes in robotic resection when compared to VATS 
with improvement in postoperative pain. Other experiences with larger cohorts 
found higher incidence of operative injury, and bleeding compared to VATS. 
Robotic-assisted operations are also significantly more costly [34]. Park et al. [35] 
reported the long-term oncologic outcomes from three institutions and found them 
to be similar to VATS lobectomies.
Rajaram et al. [36] evaluated the use of robotic surgery for stage I to IIa NSCLC 
in the National Cancer Database from 2010 to 2012. They found 62,206 patients 
who underwent lobectomies including the open (n = 45,427), VATS (n = 12,990), 
and robotic (n = 3689) techniques. They found that the over the two-year period the 
use of the robotic lobectomy technique increased by 6%. Patients who underwent a 
robotic lobectomy had a lower length of stay compared to open lobectomy but had 
a higher rate of prolonged length of stay compared to VATS. The number of lymph 
nodes examined was significantly higher in the VATS group compared to robotic, 
with no difference in number of lymph nodes in the robotic and open groups. 
The resection status, margin positivity, was comparable between all groups. The 
evaluation of this data and the known increase in cost for the robotic technique did 
not show any potential advantages to the use of robotic surgery for a lobectomy 
compared to VATS. With the use of robotic techniques in treatment for NSCLC, 
early outcomes have been evaluated. Mungo et al. [37] found no negative effect on 
outcomes in patients who underwent robotic resection.
Park et al. [38] reported long-term outcomes to be similar in robotic assisted 
lobectomies compared to VATS and open thoracotomy. Yang et al. [18] compared 
the use of robotic, VATS, and open thoracotomy in patients treated with lobectomy 
for stage I NSCLC. An advantage of the robotic approach they report is a higher 
number of mediastinal lymph node stations dissected compared to the other 
techniques. The patients treated with the minimally invasive approach, robotic 
and VATS, had shorter hospital stays. The long term outcomes were similar in all 
the groups with 5 year overall survival reported for robotic, VATS and open thora-
cotomy as 77.6%, 73.5%, and 77.9%, respectively.
Cerfolio et al. [39] demonstrated the efficacy of robotic segmentectomies. 
For 100 planned robotic segmentectomies, 7 converted to lobectomies though 
every case was completed robotically. In this cohort, there were no mortalities 
at 30 or 90 days. Only 2 patients suffered major morbidity, each of which were 
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postoperative pneumonias. Of the 79 patients that underwent robotic segmentec-
tomy, there were only 3 recurrences (3.4%) with median follow up of 30 months 
while overall survival was 95%.
9. Development of awake VATS
Optimal visualization for a VATS is typically achieved with general anesthesia 
for double lumen tube intubation. However, awake VATS under regional anesthesia 
may be appropriate for selected patients. Potential anesthetic approaches include 
intercostal nerve block, paravertebral block, thoracic epidural block, peripheral 
field block, or ipsilateral stellate ganglion block [40].
A randomized study of 43 patients by Pompeo et al. [41] assessed the feasibility 
and efficacy of awake VATS in patients with spontaneous pneumothoraces that 
require intervention. Patients were randomized to undergo VATS bullectomy and 
pleural abrasion with either thoracic epidural anesthesia or general anesthesia. The 
patients undergoing awake VATS had shorter operating room times, improved pain 
scores, and shorter hospital stays compared to the general anesthesia group. Awake 
VATS patients did suffer minor complications including vomiting and transient 
urinary retention though there was no difference in morbidity and mortality 
between groups. Recurrences at 12 months were similar in each group. Tacconi et al. 
[42] reported satisfactory lung reexpansion in 95% in 19 patients that underwent 
awake VATS for pleural decortication. A single institution study by Chen et al. [43] 
reported 285 cases of awake VATS for pathologies such as primary lung cancer, 
metastatic lung cancer, benign lung tumors, and pneumothorax. Operative inter-
ventions included lobectomies, wedge resections and segmentectomies with a 4.9% 
intubation rate.
Additionally, Chen et al. [44] examined outcomes for patient undergoing awake 
VATS in stage I and II NSCLC. For 30 patients undergoing awake VATS lobectomy 
under epidural anesthesia and intrathoracic vagal block with sedation and 30 
patients undergoing VATS lobectomy under general anesthesia with single lung ven-
tilation, there was evidence that each group had comparable pathologic stages and 
number of lymph nodes resected. Additionally, no statistical difference was seen in 
postoperative complication though the awake VATS group had shorter hospital stays 
and decreased need for chest tube drainage.
10. Conclusion
At this point in the development of minimally invasive thoracic surgery, there is 
evidence that there are advantages as well as proof of non-inferiority. Additionally, 
robotic-assisted minimally invasive surgery has been proven safe in the hands of 
those adept in it on selected patients but carries the burden of additional cost. 
Follow up data from some studies show that long term outcomes are equivalent. 
Additional study is still required to fully establish if the costs of robotic surgery are 
justified.
Update in Respiratory Diseases
8
Author details
Rachit Shah* and Nils-Tomas Delagar McBride
Virginia Commonwealth University Medical Center, USA
*Address all correspondence to: rachit.shah@vcuhealth.org
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
9Advances in Minimally Invasive Surgery for Lung Cancer
DOI: http://dx.doi.org/10.5772/intechopen.93102
References
[1] Roviaro GC, Rebuffat C, Varoli F, 
Vergani C, Mariani C, Maciocco M. 
Videoendoscopic pulmonary lobectomy 
for cancer. Surgical Laparoscopy & 
Endoscopy. 1992;2:244-247
[2] Gordon S. Clinical reports of rare 
cases, occurring in the Whitworth and 
Harwicke Hospitals. Dublin Quarterly 
Journal of Medical Science. 1866
[3] Koch R. “Die Aetiologie der 
Tuberculose” [The etiology of 
tuberculosis]. Berliner Klinische 
Wochenschrift (Berlin Clinical Weekly). 
1882;19:221-230
[4] Forlanini C. A contribuzioni della 
terapia chirurgica della tisi-Ablazione 
del polmone? Pneumotorace artificiale? 
Gazz Osp. 1882;3(68):53729, 585-587, 
601-602, 609-610, 617-619, 625-627, 
641-643, 657-660, 665-667, 689-691, 
705-707
[5] Jacobaeus H. Ueber die moglichkeit 
die zystoskopie bei untersuchung 
seroser Honlungen Munchen. 
Deutsche Medizinische Wchenschrift. 
1910;57:2090-2092
[6] Sihoe AD. The evolution of 
minimally invasive thoracic surgery: 
Implications for the practice of 
uniportal thoracoscopic surgery. Journal 
of Thoracic Disease. 2014;6(Suppl 6): 
S604-S617. DOI: 10.3978/j.
issn.2072-1439.2014.08.52
[7] Kirby TJ, Mack MJ, Landreneau RJ, 
Rice TW. Lobectomy–video-assisted 
thoracic surgery versus muscle-sparing 
thoracotomy. A randomized trial. The 
Journal of Thoracic and Cardiovascular 
Surgery. 1995;109(5):997-1001; 
discussion -2
[8] McKenna RJ Jr, Wolf RK, Brenner M, 
Fischel RJ, Wurnig P. Is lobectomy 
by video-assisted thoracic surgery 
an adequate cancer operation? 
The Annals of Thoracic Surgery. 
1998;66(6):1903-1908
[9] Li Y, Wang J. Comparison of clinical 
outcomes for patients with clinical N0 
and pathologic N2 non-small cell lung 
cancer after thoracoscopic lobectomy 
and open lobectomy: A retrospective 
analysis of 76 patients. Journal of 
Surgical Oncology. 2012;106(4):431-435
[10] Onaitis MW, Petersen RP, 
Balderson SS, Toloza E, Burfeind WR, 
Harpole DH Jr, et al. Thoracoscopic 
lobectomy is a safe and versatile 
procedure: Experience with 500 
consecutive patients. Annals of Surgery. 
2006;244(3):420-425
[11] Whitson BA, Andrade RS, 
Boettcher A, Bardales R, Kratzke RA, 
Dahlberg PS, et al. Video-assisted 
thoracoscopic surgery is more favorable 
than thoracotomy for resection of 
clinical stage I non-small cell lung 
cancer. The Annals of Thoracic Surgery. 
2007;83(6):1965-1970
[12] Shigemura N, Akashi A, Funaki S, 
Nakagiri T, Inoue M, Sawabata N, et al. 
Long-term outcomes after a variety of 
video-assisted thoracoscopic lobectomy 
approaches for clinical stage IA lung 
cancer: A multi-institutional study. The 
Journal of thoracic and cardiovascular 
surgery. 2006;132(3):507-512
[13] Higuchi M, Yaginuma H, Yonechi A, 
Kanno R, Ohishi A, Suzuki H, et al. 
Long-term outcomes after video-
assisted thoracic surgery (VATS) 
lobectomy versus lobectomy via open 
thoracotomy for clinical stage IA 
non-small cell lung cancer. Journal of 
Cardiothoracic Surgery. 2014;9:88
[14] Lee PC, Nasar A, Port JL, Paul S, 
Stiles B, Chiu YL, et al. Long-term 
survival after lobectomy for non-small 
cell lung cancer by video-assisted 
thoracic surgery versus thoracotomy. 
Update in Respiratory Diseases
10
The Annals of Thoracic Surgery. 
2013;96(3):951-960; discussion 60-1
[15] Murakawa T, Ichinose J, Hino H, 
Kitano K, Konoeda C, Nakajima J. 
Long-term outcomes of open and 
video-assisted thoracoscopic lung 
lobectomy for the treatment of early 
stage non-small cell lung cancer 
are similar: A propensity-matched 
study. World Journal of Surgery. 
2015;39(5):1084-1091
[16] Yang CF, Meyerhoff RR, Mayne NR, 
Singhapricha T, Toomey CB, 
Speicher PJ, et al. Long-term survival 
following open versus thoracoscopic 
lobectomy after preoperative 
chemotherapy for non-small cell lung 
cancer. European Journal of Cardio-
thoracic Surgery: Official Journal of 
the European Association for Cardio-
Thoracic Surgery. 2016;49(6):1615-1623
[17] Flores RM, Park BJ, Dycoco J, 
Aronova A, Hirth Y, Rizk NP, et al. 
Lobectomy by video-assisted thoracic 
surgery (VATS) versus thoracotomy 
for lung cancer. The Journal of 
Thoracic and Cardiovascular Surgery. 
2009;138(1):11-18
[18] Yang HX, Woo KM, Sima CS, 
Bains MS, Adusumilli PS, Huang J, 
et al. Long-term survival based on 
the surgical approach to lobectomy 
for clinical stage I nonsmall cell lung 
Cancer: Comparison of robotic, 
video-assisted thoracic surgery, and 
thoracotomy lobectomy. Annals of 
Surgery. 2017;265(2):431-437
[19] D’Amico TA, Niland J, Mamet R, 
Zornosa C, Dexter EU, Onaitis MW. 
Efficacy of mediastinal lymph node 
dissection during lobectomy for 
lung cancer by thoracoscopy and 
thoracotomy. The Annals of Thoracic 
Surgery. 2011;92(1):226-231; Discussion 
31-2
[20] Palade E, Passlick B, Osei-Agyemang 
T, Gunter J, Wiesemann S. Video-assisted 
vs open mediastinal lymphadenectomy 
for stage I non-small-cell lung cancer: 
Results of a prospective randomized 
trial. European Journal of Cardio-
Thoracic Surgery: Official Journal of 
the European Association for Cardio-
Thoracic Surgery. 2013;44(2):244-249; 
Discussion 9
[21] Villamizar NR, Darrabie MD, 
Burfeind WR, Petersen RP, 
Onaitis MW, Toloza E, et al. 
Thoracoscopic lobectomy is associated 
with lower morbidity compared 
with thoracotomy. The Journal of 
Thoracic and Cardiovascular Surgery. 
2009;138(2):419-425
[22] Paul S, Altorki NK, Sheng S, 
Lee PC, Harpole DH, Onaitis MW, 
et al. Thoracoscopic lobectomy is 
associated with lower morbidity than 
open lobectomy: A propensity-matched 
analysis from the STS database. The 
Journal of Thoracic and Cardiovascular 
Surgery. 2010;139(2):366-378
[23] Donahoe LL, de Valence M, 
Atenafu EG, Hanna WC, Waddell TK, 
Pierre AF, et al. High risk for 
thoracotomy but not thoracoscopic 
lobectomy. The Annals of Thoracic 
Surgery. 2017
[24] Bertani A, Ferrari PA, De Monte L, 
Russo E, Di Paola G. Video-assisted 
thoracic surgery lobectomy in patients 
with reduced pulmonary function: A 
single-center series. Future Oncology 
(London, England). 2016;12(23s):39-45
[25] Swanson SJ, Meyers BF, 
Gunnarsson CL, Moore M, 
Howington JA, Maddaus MA, 
et al. Video-assisted thoracoscopic 
lobectomy is less costly and morbid 
than open lobectomy: A retrospective 
multiinstitutional database analysis. 
The Annals of Thoracic Surgery. 
2012;93(4):1027-1032
[26] Schuchert MJ, Pettiford BL, 
Pennathur A, Abbas G, Awais O, 
11
Advances in Minimally Invasive Surgery for Lung Cancer
DOI: http://dx.doi.org/10.5772/intechopen.93102
Close J, et al. Anatomic segmentectomy 
for stage I non-small-cell lung cancer: 
Comparison of video-assisted thoracic 
surgery versus open approach. The 
Journal of Thoracic and Cardiovascular 
Surgery. 2009;138(6):1318-25.e1
[27] Liu Y, Gao Y, Zhang H, Cheng Y, 
Chang R, Zhang W, et al. Video-assisted 
versus conventional thoracotomy 
pneumonectomy: A comparison of 
perioperative outcomes and short-term 
measures of convalescence. Journal of 
Thoracic Disease. 2016;8(12):3537-3542
[28] Rocco G, Martin-Ucar A, Passera E. 
Uniportal VATS wedge pulmonary 
resections. The Annals of Thoracic 
Surgery. 2004;77(2):726-728
[29] Xie D, Wang H, Fei K, Chen C, 
Zhao D, Zhou X, et al. Single-port video-
assisted thoracic surgery in 1063 cases: 
A single-institution experiencedagger. 
European Journal of Cardio-Thoracic 
Surgery: Official Journal of the European 
Association for Cardio-thoracic Surgery. 
2016;49(Suppl 1):i31-i36
[30] Shih CS, Liu CC, Liu ZY, 
Pennarun N, Cheng CT. Comparing 
the postoperative outcomes of video-
assisted thoracoscopic surgery (VATS) 
segmentectomy using a multi-port 
technique versus a single-port technique 
for primary lung cancer. Journal of 
Thoracic Disease. 2016;8(Suppl 3): 
S287-S294
[31] Dai F, Meng S, Mei L, Guan C, 
Ma Z. Single-port video-assisted 
thoracic surgery in the treatment 
of non-small cell lung cancer: A 
propensity-matched comparative 
analysis. Journal of Thoracic Disease. 
2016;8(10):2872-2878
[32] Fan J, Yao J, Wang Q , Chang Z. 
Safety and feasibility of uniportal 
video-assisted thoracoscopic surgery 
for locally advanced non-small cell lung 
cancer. Journal of Thoracic Disease. 
2016;8(12):3543-3550
[33] Melfi FM, Menconi GF, 
Mariani AM, Angeletti CA. Early 
experience with robotic technology 
for thoracoscopic surgery. European 
Journal of Cardio-Thoracic Surgery: 
Official Journal of the European 
Association for Cardio-thoracic Surgery. 
2002;21(5):864-868
[34] Park BJ, Flores RM. Cost 
comparison of robotic, video-
assisted thoracic surgery and 
thoracotomy approaches to pulmonary 
lobectomy. Thoracic Surgery Clinics. 
2008;18(3):297-300; vii
[35] Park BJ. Robotic lobectomy for 
non-small cell lung cancer: Long-term 
oncologic results. Thoracic Surgery 
Clinics. 2014;24(2):157-162; vi
[36] Rajaram R, Mohanty S, Bentrem DJ, 
Pavey ES, Odell DD, Bharat A, et al. 
Nationwide assessment of robotic 
lobectomy for non-small cell lung 
cancer. The Annals of Thoracic Surgery. 
2017;103(4):1092-1100
[37] Mungo B, Hooker CM, Ho JS, 
Yang SC, Battafarano RJ, Brock MV, 
et al. Robotic versus thoracoscopic 
resection for lung cancer: Early 
results of a new robotic program. 
Journal of Laparoendoscopic & 
Advanced Surgical Techniques Part A. 
2016;26(4):243-248
[38] Park BJ, Melfi F, Mussi A, 
Maisonneuve P, Spaggiari L, Da 
Silva RK, et al. Robotic lobectomy for 
non-small cell lung cancer (NSCLC): 
Long-term oncologic results. The 
Journal of Thoracic and Cardiovascular 
Surgery. 2012;143(2):383-389
[39] Cerfolio RJ, Watson C, Minnich 
DJ, Calloway S, Wei B. One hundred 
planned robotic segmentectomies: Early 
results, technical details, and preferred 
Port placement. The Annals of Thoracic 
Surgery. 2016 Mar;101(3):1089-1095; 
Discussion 1095-1096. DOI: 10.1016/j.
Update in Respiratory Diseases
12
athoracsur.2015.08.092. [Epub: 02 
February 2016]
[40] Kao MC, Lan CH, Huang CJ. 
Anesthesia for awake video-assisted 
thoracic surgery. Acta Anaesthesiologica 
Taiwanica: Official Journal of the 
Taiwan Society of Anesthesiologists. 
2012;50(3):126-130
[41] Pompeo E, Tacconi F, Mineo D, 
Mineo TC. The role of awake video-
assisted thoracoscopic surgery in 
spontaneous pneumothorax. The 
Journal of Thoracic and Cardiovascular 
Surgery. 2007;133(3):786-790
[42] Tacconi F, Pompeo E, Fabbi E, 
Mineo TC. Awake video-assisted 
pleural decortication for empyema 
thoracis. European Journal of Cardio-
Thoracic Surgery: Official Journal of 
the European Association for Cardio-
Thoracic Surgery. 2010;37(3):594-601
[43] Chen KC, Cheng YJ, Hung MH, 
Tseng YD, Chen JS. Nonintubated 
thoracoscopic lung resection: A 3-year 
experience with 285 cases in a single 
institution. Journal of Thoracic Disease. 
2012;4(4):347-351
[44] Chen JS, Cheng YJ, Hung MH, 
Tseng YD, Chen KC, Lee YC. 
Nonintubated thoracoscopic lobectomy 
for lung cancer. Annals of Surgery. 
2011;254(6):1038-1043
